结肠癌不可切除转移患者全身治疗前原发肿瘤切除:SYNCHRONOUS与CCRe-IV试验合并结果
该分析纳入多中心随机SYNCHRONOUS和CCRe-IV试验中393例结肠癌伴同时性不可切除转移患者,随机接受原发肿瘤切除(PTR组187例)或 upfront 化疗(无PTR组206例)。中位随访36.7个月,PTR组中位总生存16.7个月 vs 无PTR组18.6个月(P=0.191),多变量分析HR 0.944(95%CI 0.738-1.209,P=0.65)。结论认为全身化疗前PTR与总生存延长无关。
要点
- 结肠癌同时性不可切除转移患者中,化疗前原发肿瘤切除未延长总生存。
- PTR组中位OS 16.7个月 vs 无PTR组18.6个月,差异未达统计学显著(P=0.191)。
- 无PTR组严重不良事件发生率18.0% vs PTR组10.2%(P=0.027)。
核心结论
- 在结肠癌伴同时性不可切除转移患者中,全身化疗前原发肿瘤切除与总生存延长无关。
研究设计与样本
- 研究纳入多中心、随机SYNCHRONOUS和CCRe-IV试验中结肠癌伴同时性不可切除转移的患者。
- 患者于奥地利、德国和西班牙的100个中心随机分配接受原发肿瘤切除(PTR组187例)或 upfront 化疗(无PTR组206例),化疗方案由当地团队决定。
- 排除有肿瘤相关症状、无法耐受手术和/或全身化疗、有其他癌症史的患者。
- 主要终点为总生存(OS),采用意向性治疗分析。
- 2011年11月至2017年3月期间共393例患者随机分组。
主要发现
- 中位随访时间36.7个月(95%CI 36.6-37.3)。
- PTR组中位OS为16.7个月(95%CI 13.2-19.2),无PTR组为18.6个月(95%CI 16.2-22.3),P=0.191。
- 多变量分析显示两组OS无显著差异(HR 0.944,95%CI 0.738-1.209,P=0.65),且在所有亚组中一致。
- 无PTR组未接受化疗者占6.4%,PTR组占24.1%。
- 无PTR组严重不良事件发生率18.0%,PTR组10.2%(P=0.027)。
临床怎么用
- 原文结论未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Chemotherapy is established as primary treatment in patients with stage IV colorectal cancer and unresectable metastases. Data from nonrandomized clinical trials have fueled persistent uncertainty if primary tumor resection (PTR) before chemotherapy prolongs survival. We investigated the prognostic value of PTR in patients with newly diagnosed stage IV colon cancer who were not amenable to curative treatment. PATIENTS AND METHODS: Patients enrolled in the multicenter, randomized SYNCHRONOUS and CCRe-IV trials were included in the analysis. Patients with colon cancer with synchronous unresectable metastases were randomly assigned at 100 sites in Austria, Germany, and Spain to undergo PTR or up-front chemotherapy (No PTR group). The chemotherapy regimen was left at discretion of the local team. Patients with tumor-related symptoms, inability to tolerate surgery and/or systemic chemotherapy, and history of another cancer were excluded. The primary end point was overall survival (OS), and the analyses were performed with intention-to-treat. RESULTS: A total of 393 patients were randomly assigned to undergo PTR (n = 187) or no PTR (n = 206) between November 2011 and March 2017. Chemotherapy was not administered to 6.4% in the No PTR group and 24.1% in the PTR group. The median follow-up time was 36.7 months (95% CI, 36.6 to 37.3). The median OS was 16.7 months (95% CI, 13.2 to 19.2) in the PTR group and 18.6 months (95% CI, 16.2 to 22.3) in the No PTR group (P = .191). Comparable OS between the study groups was further confirmed on multivariate analysis (hazard ratio, 0.944 [95% CI, 0.738 to 1.209], P = .65) and across all subgroups. Patients with serious adverse events were more common in the No PTR group (10.2% v 18.0%; P = .027). CONCLUSION: Among patients with colon cancer and synchronous unresectable metastases, PTR before systemic chemotherapy was not associated with prolonged OS.
引用
- Rahbari NN, Biondo S, Frago R, et al. Primary Tumor Resection Before Systemic Therapy in Patients With Colon Cancer and Unresectable Metastases: Combined Results of the SYNCHRONOUS and CCRe-IV Trials. J Clin Oncol. 2024. PMID: 38412408. doi:10.1200/JCO.23.01540
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。